The aim of the proposed study is to evaluate the effects of high dose nicotine (HDN) infusion on nicotine self-administration (NSA) in rats. HDN safety and pharmacokinetics will also be studied. The long term goal of this work is to evaluate the potential of HDN as an adjunct to smoking cessation in patients refractory to standard therapies. Nicotine replacement therapy enhances smoking cessation rates, but most quit attempts are still unsuccessful. However, nicotine replacement therapy typically provides venous plasma nicotine concentrations that are substantially lower than those associated with smoking. Higher than usual doses of nicotine replacement, e.g. 2 nicotine patches at once, have been only equivocally successful in enhancing quit rates compared to usual doses, but even these higher doses do not provide the very high arterial nicotine concentrations associated with cigarette smoking. Whether even higher doses of nicotine (providing smokers with venous and arterial nicotine concentrations exceeding those experienced during normal smoking) would confer additional benefit is not known. Potential advantages of this level of HDN include more complete suppression of withdrawal, craving, and the rewarding effects of smoking. Hvpotheses to be tested are that 1) HDN suppresses the maintenance and reinstatement of NSA, 2) RDN is safe owing to the rapid development of tolerance to its adverse effects, 3) HDN efficacy can be augmented by combining it with the nicotinic antagonist mecamylamine, 4) the pharmacokinetics of HDN is similar to that of usual replacement doses, and 5) HDN reduces the formation of some carcinogens from tobacco. Studies will be performed in rats because the safety of administering HDN at the proposed doses to humans is untested. The effects of HDN on the maintenance of ongoing NSA and the reinstatement of nicotine responding will be examined. A range of both HDN doses and NSA doses will be used to establish dose-response relationships. The physiologic effects and safety of these treatments will be evaluated. HDN will be combined with the nicotinic antagonist mecamylamine to determine whether this combination is more effective than HDN alone, or better tolerated. The pharmacokinetics of HDN compared to usual nicotine replacement doses will be studied to aid in HDN dose selection. The formation of carcinogenic metabolites from the tobacco nitrosarnine NNK will be studied to determine whether this rate is altered when HDN and NNK are co-administered. Taken together, these studies will address the feasibility of using HDN as an adjunct to the initiation or maintenance of smoking cessation, and whether it is safe enough for testing in humans.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
3P50DA013333-04S1
Application #
6668298
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-09-30
Project End
2003-08-31
Budget Start
Budget End
Support Year
4
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
168559177
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Burns, Rachel J; Rothman, Alexander J; Fu, Steven S et al. (2016) Longitudinal Care Improves Cessation in Smokers Who Do Not Initially Respond to Treatment by Increasing Cessation Self-Efficacy, Satisfaction, and Readiness to Quit: A Mediated Moderation Analysis. Ann Behav Med 50:58-69
Konorev, Dmitri; Koopmeiners, Joseph S; Tang, Yijin et al. (2015) Measurement of the Heterocyclic Amines 2-Amino-9H-pyrido[2,3-b]indole and 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in Urine: Effects of Cigarette Smoking. Chem Res Toxicol 28:2390-9
Hatsukami, Dorothy K; Donny, Eric C; Koopmeiners, Joseph S et al. (2015) Compensatory smoking from gradual and immediate reduction in cigarette nicotine content. Cancer Epidemiol Biomarkers Prev 24:472-6
Burns, Rachel J; Rothman, Alexander J; Fu, Steven S et al. (2014) The relation between social support and smoking cessation: revisiting an established measure to improve prediction. Ann Behav Med 47:369-75
Oliver, Andrew J; Jensen, Joni A; Vogel, Rachel I et al. (2013) Flavored and nonflavored smokeless tobacco products: rate, pattern of use, and effects. Nicotine Tob Res 15:88-92
Knezevich, Aleksandar; Muzic, John; Hatsukami, Dorothy K et al. (2013) Nornicotine nitrosation in saliva and its relation to endogenous synthesis of N'-nitrosonornicotine in humans. Nicotine Tob Res 15:591-5
Anderson, Kristin E; Mongin, Steven J; Sinha, Rashmi et al. (2012) Pancreatic cancer risk: associations with meat-derived carcinogen intake in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) cohort. Mol Carcinog 51:128-37
Stepanov, Irina; Knezevich, Aleksandar; Zhang, Liqin et al. (2012) Carcinogenic tobacco-specific N-nitrosamines in US cigarettes: three decades of remarkable neglect by the tobacco industry. Tob Control 21:44-8
Hecht, Stephen S; Stepanov, Irina; Hatsukami, Dorothy K (2011) Major tobacco companies have technology to reduce carcinogen levels but do not apply it to popular smokeless tobacco products. Tob Control 20:443
Harris, Andrew C; Pentel, Paul R; Burroughs, Danielle et al. (2011) A lack of association between severity of nicotine withdrawal and individual differences in compensatory nicotine self-administration in rats. Psychopharmacology (Berl) 217:153-66

Showing the most recent 10 out of 132 publications